TG Therapeutics Inc. (NASDAQ: TGTX) announced March 9 that data from a pooled analysis of Phase 3 trials showed its multiple sclerosis drug BRIUMVI reduced relapse rates and brain lesions in patients with highly active disease, according to research published in Neurology and Therapy.

The analysis examined 168 participants with highly active relapsing multiple sclerosis from the ULTIMATE I and II studies. Patients receiving BRIUMVI showed a 70.8% reduction in annualized relapse rate compared to those taking teriflunomide over 96 weeks.

BRIUMVI reduced gadolinium-enhancing brain lesions by 83.3% at 12 weeks and 95.6% over the full study period. New or enlarging T2 lesions decreased by 57.5% at 12 weeks and 91.1% during the complete trial period.

The study defined highly active disease as patients having two or more relapses in the previous year and at least one gadolinium-enhancing lesion at baseline. These patients face higher risk for rapid disease progression.

BRIUMVI achieved no evidence of disease activity in 77.9% of patients during weeks 24-96 compared to 16.4% with teriflunomide. The drug received FDA approval for treating adult patients with relapsing forms of multiple sclerosis.

The ULTIMATE trials enrolled 1,094 patients across 10 countries and compared BRIUMVI to teriflunomide over 96 weeks. TG Therapeutics focuses on developing treatments for B-cell diseases and has commercialized BRIUMVI in the United States and several other countries.